Acute kidney injury (AKI) is common among patients undergoing cardiopulmonary bypass (CPB) surgery. AKI diagnosis relies on serum creatinine and urine output which show poor sensitivity and specificity. New AKI biomarkers have not been widely adopted into clinical care due to limitations. A shortcoming of existing AKI biomarkers is lack of kidney tissue specificity. We previously described the kidney specific enzyme, myo-inositol oxygenase (MIOX), as a potential plasma AKI biomarker. In this study, we evaluated urine MIOX as an AKI biomarker in patients undergoing CPB surgery and compare MIOX with kidney injury molecule-1 (KIM-1) and neutrophil gelatinase associated lipocalin (NGAL).
No takes yet. Share an insight, caveat, or question.
Gaut et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: